Abeona Therapeutics, Inc. (ABEO)
6.075
-0.02
(-0.25%)
USD |
NASDAQ |
Aug 24, 16:00
6.075
0.00 (0.00%)
After-Hours: 20:00
Abeona Therapeutics Enterprise Value : 221.55M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 221.55M |
| August 20, 2026 | 214.11M |
| August 19, 2026 | 223.84M |
| August 18, 2026 | 225.56M |
| August 17, 2026 | 212.97M |
| August 14, 2026 | 215.54M |
| August 13, 2026 | 236.14M |
| August 12, 2026 | 299.95M |
| August 11, 2026 | 296.52M |
| August 10, 2026 | 299.38M |
| August 07, 2026 | 287.36M |
| August 06, 2026 | 267.90M |
| August 05, 2026 | 262.18M |
| August 04, 2026 | 263.33M |
| August 03, 2026 | 238.72M |
| July 31, 2026 | 240.44M |
| July 30, 2026 | 243.30M |
| July 29, 2026 | 229.56M |
| July 28, 2026 | 217.55M |
| July 27, 2026 | 223.84M |
| July 24, 2026 | 219.26M |
| July 23, 2026 | 238.15M |
| July 22, 2026 | 240.44M |
| July 21, 2026 | 246.73M |
| July 20, 2026 | 243.87M |
| Date | Value |
|---|---|
| July 17, 2026 | 273.63M |
| July 16, 2026 | 274.77M |
| July 15, 2026 | 290.22M |
| July 14, 2026 | 277.06M |
| July 13, 2026 | 274.20M |
| July 10, 2026 | 272.48M |
| July 09, 2026 | 280.49M |
| July 08, 2026 | 262.18M |
| July 07, 2026 | 247.88M |
| July 06, 2026 | 234.14M |
| July 02, 2026 | 239.29M |
| July 01, 2026 | 219.26M |
| June 30, 2026 | 226.70M |
| June 29, 2026 | 176.77M |
| June 26, 2026 | 173.92M |
| June 25, 2026 | 171.08M |
| June 24, 2026 | 174.49M |
| June 23, 2026 | 180.18M |
| June 22, 2026 | 181.88M |
| June 18, 2026 | 183.02M |
| June 17, 2026 | 176.20M |
| June 16, 2026 | 176.20M |
| June 15, 2026 | 177.33M |
| June 12, 2026 | 169.37M |
| June 11, 2026 | 169.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Corcept Therapeutics, Inc. | 12.89B |
| Forum Markets, Inc. | 94.24M |
| ACADIA Pharmaceuticals, Inc. | 4.195B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| Anika Therapeutics, Inc. | 278.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 11.38M |
| Total Expenses (Quarterly) | 31.57M |
| EPS Diluted (Quarterly) | -0.3539 |
| Gross Profit Margin (Quarterly) | 57.45% |
| Profit Margin (Quarterly) | -177.4% |
| Earnings Yield | -18.48% |
| Normalized Earnings Yield | -19.02 |